Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like Stanford University Clinical Geneticist Begins Presidency With The March 22, 2017 Former Schering-Plough CEO Says This is the 'Worst Solution' to the Drug Pricing Dilemma August 24, 2017 Bay Area's GigaGen Moves to New Space to Accommodate Growth January 22, 2018
Former Schering-Plough CEO Says This is the 'Worst Solution' to the Drug Pricing Dilemma August 24, 2017
